Cushing Disease Clinical Trials and Treatments

Cushing Disease results from ACTH overproduction by a pituitary adenoma, stimulating excessive cortisol synthesis by the adrenal glands. Excess cortisol causes multiple systemic effects through glucocorticoid receptor activation. Characteristic appearance results from central fat redistribution with abdominal and dorsocervical obesity, supraclavicular fat pads ('buffalo hump'), and facial plethora ('moon facies').

The most common symptoms of Cushing Disease include Central obesity with 'buffalo hump' and supraclavicular fat pads, Round 'moon face' with facial plethora, Wide purple stretch marks (striae) on abdomen, thighs, and arms, Easy bruising and thin fragile skin, Proximal muscle weakness and wasting, among others. Estimated 2-8 new cases per million people per year, though recent population studies suggest the true incidence may be higher. Cushing disease (pituitary-dependent) accounts for about 70% of endogenous Cushing syndrome cases. More common in women (3:1 female-to-male ratio). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Cushing Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Transsphenoidal surgery by an experienced pituitary neurosurgeon remains the first-line treatment for Cushing disease. When surgery doesn't fully normalize cortisol, 4 FDA-approved medications are now available: pasireotide (Signifor) suppresses ACTH secretion from the pituitary, osilodrostat (Isturisa) and levoketoconazole (Recorlev) block cortisol production in the adrenal glands, and mifepristone (Korlym) blocks cortisol's effects at the receptor level.

Four FDA-approved medications target Cushing disease or Cushing syndrome. Pasireotide (Signifor, Signifor LAR) is a somatostatin analog approved specifically for Cushing's disease; it suppresses ACTH secretion from the pituitary adenoma via somatostatin receptor subtype 5. Osilodrostat (Isturisa) blocks cortisol synthesis by inhibiting 11-beta-hydroxylase in the adrenal gland, with expanded approval in 2025 for all adults with Cushing syndrome. Mifepristone (Korlym) blocks the glucocorticoid receptor, indicated for hyperglycemia secondary to hypercortisolism in adults with Cushing syndrome who have type 2 diabetes or glucose intolerance. Levoketoconazole (Recorlev) inhibits multiple steroidogenic enzymes to reduce cortisol levels. Off-label medications including ketoconazole, metyrapone, cabergoline, and mitotane are also used. Transsphenoidal surgery by an experienced neurosurgeon remains the primary treatment. Always consult your endocrinologist about which approach is right for your situation.

Cushing disease is caused by a benign ACTH-secreting pituitary adenoma (corticotroph adenoma) that overproduces adrenocorticotropic hormone, driving the adrenal glands to synthesize excessive cortisol. Most tumors are microadenomas (<10mm) and arise from somatic mutations, with USP8 mutations found in roughly half of cases. The excess cortisol affects nearly every organ system through glucocorticoid receptor activation, causing central fat redistribution, metabolic syndrome, bone loss, immune suppression, and psychiatric symptoms. Cushing disease accounts for approximately 70% of all endogenous Cushing syndrome cases. Diagnosis is complex, requiring stepwise confirmation of hypercortisolism (24-hour urinary free cortisol, late-night salivary cortisol, dexamethasone suppression testing) followed by ACTH-dependent source identification through inferior petrosal sinus sampling and pituitary MRI.

For Cushing Disease the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA, looking for USP8. Caused by an ACTH-secreting pituitary adenoma; somatic USP8 variants are the most common genetic finding in the tumor, and the disease is sporadic unless part of a syndrome such as MEN1.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Cushing Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Cushing Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.

Cushing disease clinical trials frequently exclude patients currently taking cortisol-modifying medications without adequate washout periods. FDA-approved therapies including pasireotide (Signifor), osilodrostat (Isturisa), mifepristone (Korlym), and levoketoconazole (Recorlev) typically require 4 to 8 week washouts before enrollment in trials testing new agents. Off-label medications like ketoconazole, metyrapone, and cabergoline may also need discontinuation. Exogenous corticosteroids are almost universally excluded. Trial Friend's medication conflict checker scans each trial's exclusion criteria against common Cushing's medications including steroidogenesis inhibitors, glucocorticoid receptor antagonists, somatostatin analogs, dopamine agonists, and supportive care drugs. Strong CYP3A4 modulators (rifampin, carbamazepine) are frequently excluded due to drug interactions. The checker flags the specific drug, the trial's exclusion language, and a confidence level so you can discuss timing with your endocrinologist.

Key questions to ask your endocrinologist about Cushing disease clinical trials include: Has my pituitary adenoma been confirmed by inferior petrosal sinus sampling, and does the tumor size affect which trials I qualify for? If transsphenoidal surgery didn't fully normalize my cortisol, am I a candidate for medical therapy trials? What washout period would I need from my current medication (pasireotide, osilodrostat, ketoconazole, mifepristone) before enrolling? Are there trials testing combination approaches or newer mechanisms like ACTH receptor antagonists? What are my current 24-hour urinary free cortisol and late-night salivary cortisol levels, and do they meet trial entry criteria? How would stopping my current cortisol-lowering medication during a washout affect my symptoms, and what safety monitoring would be in place? Should I consider pituitary radiation as a bridge while waiting for a trial opportunity?